| 词条 | NS-2359 |
| 释义 |
| verifiedrevid = 424915685 | IUPAC_name = (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane | image = NStwothreefivenine.png | tradename = | ATC_prefix = none | PubChem = 11408320 | C=15 | H=19 | Cl=2 | N=1 | O=1 | molecular_weight = 300.223 g/mol | smiles = Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3 }}NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4] Another scientific article on NS-2359 was recently (2011) published.[5] As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression. See also
References1. ^1 {{cite web | url = https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=313018&messageId=372903 | title = NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression | format = | accessdate = }} {{Monoamine reuptake inhibitors}}{{Phenyltropanes}}{{nervous-system-drug-stub}}2. ^{{Cite journal| journal = Behavioral and Brain Functions| title = A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD | first7 = B.| last7 = Mikkelsen| volume = 4| pages = 24| doi = 10.1186/1744-9081-4-24| pmc = 2442604| pmid = 18554401| year = 2008 | first6 = O.| last6 = Graff| last3 = Adler | first2 = T.| last2 = Klint | first1 = T. E. | first3 = L.| last4 = West | first5 = K.| last5 = Wesnes | first4 = S.| last1 = Wilens }} 3. ^Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder - Full Text View - ClinicalTrials.gov 4. ^Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1 - Full Text View - ClinicalTrials.gov 5. ^{{Cite journal | last1 = Learned | first1 = S. | last2 = Graff | first2 = O. | last3 = Roychowdhury | first3 = S. | last4 = Moate | first4 = R. | last5 = Krishnan | first5 = K. R. | last6 = Archer | first6 = G. | last7 = Modell | first7 = J. G. | last8 = Alexander | first8 = R. | last9 = Zamuner | first9 = S. | last10 = Lavergne | first10 = A. | last11 = Evoniuk | first11 = G. | last12 = Ratti | first12 = E. | title = Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials | doi = 10.1177/0269881111424931 | journal = Journal of Psychopharmacology | year = 2011 | pmid = 22048884 | pmc = | volume=26 | issue=5 | pages=653–662}} 5 : Ethers|Serotonin-norepinephrine-dopamine reuptake inhibitors|Chloroarenes|Tropanes|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。